ST. LOUIS (EGMN) -Accelerated partial breast irradiation using the MammoSite device continues to be well tolerated by patients with ductal carcinoma in situ, results from an ongoing registry trial showed.Superior cosmesis occurred in patients with the greatest device-to-skin distance, and the 5-year actuarial local recurrence rate was 3.39%, Dr. Jacqueline S. Jeruss reported at a symposium sponsored by the Society of Surgical Oncology. "For patients who are candidates for lumpectomy and have DCIS...